SM-368229, a novel selective and potent non-steroidal mineralocorticoid receptor antagonist with strong urinary Na+ excretion activity

Journal of Pharmacological Sciences

Volumn 115, Issue 3, 2011, Pages 346-353

  Nariai, Tetsuro ^a   Fujita, Katsuya ^a   Mori, Masaya ^a   Katayama, Seiji ^a   Hori, Seiji ^a   Matsui, Kazuki ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

Aldosterone; Eplerenone; Mineralocorticoid receptor (MR); Spironolactone; Steroid hormone

Indexed keywords

ANDROGEN; DEOXYCORTICOSTERONE ACETATE; EPLERENONE; GLUCOCORTICOID RECEPTOR; METHYLTESTOSTERONE; MINERALOCORTICOID RECEPTOR ANTAGONIST; N 4,4 DIMETHYL 2 THIOXO 1,4 DIHYDRO 2H 3,1 BENZOXAZIN 6 YL THIOPHENE 2 SULFONAMIDE; PROGESTERONE; RECEPTOR BLOCKING AGENT; SM 368229; SPIRONOLACTONE; STEROID RECEPTOR; UNCLASSIFIED DRUG;

ADRENALECTOMY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING ASSAY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; FEMALE; HEART FAILURE; HYPERTENSION; IC 50; MALE; NONHUMAN; POTASSIUM URINE LEVEL; RAT; REPORTER GENE; SODIUM URINE LEVEL;

EID: 79952786293     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.10285FP     Document Type: Article

References (29)

1. Struthers A, Krum H, Williams GH. A comparison of the aldosterone- blocking agents eplerenone and spironolactone. Clin Cardiol. 2008;31:153-158. (Pubitemid 351556480)
2. Muldowney JA 3rd, Schoenhard JA, Benge CD. The clinical pharmacology of eplerenone. Expert Opin Drug Metab Toxicol. 2009;5:425-432.
3. Maron BA, Leopold JA. Aldosterone receptor antagonists: effective but often forgotten. Circulation. 2010;121:934-939.
4. Nishiyama A, Hasegawa K, Diah S, Hitomi H. New approaches to blockade of the renin-angiotensin-aldosterone system: mineralocorticoid-receptor blockers exert antihypertensive and renoprotective effects independently of the renin-angiotensin system. J Pharmacol Sci. 2010;113:310-314.
5. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717. (Pubitemid 29407370)
6. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321. (Pubitemid 36384098)
7. Jeunemaitre X, Chatellier G, Kreft-Jais C, Charru A, DeVries C, Plouin PF, et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol. 1987;60:820-825. (Pubitemid 17163442)
8. Hu X, Li S, McMahon EG, Lala DS, Rudolph AE. Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone. Mini Rev Med Chem. 2005;5:709-718. (Pubitemid 41051894)
9. de Gasparo M, Joss U, Ramjoue HP, Whitebread SE, Haenni H, Schenkel L, et al. Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther. 1987;240:650-656. (Pubitemid 17018455)
10. Cook CS, Berry LM, Bible RH, Hribar JD, Hajdu E, Liu NW. Pharmacokinetics and metabolism of [14C]eplerenone after oral administration to humans. Drug Metab Dispos. 2003;31:1448-1455. (Pubitemid 37310335)
11. Cook CS, Zhang L, Ames GB, Fischer J, Zhang J, Levin S. Single-and repeated-dose pharmacokinetics of eplerenone, a selective aldosterone receptor blocker, in rats. Xenobiotica. 2003;33:305-321. (Pubitemid 36408198)
12. Murase H, Yasuda K, Mercado-Asis LB, Mori A, Shimada T, Mune T, et al. 19-hydroxyandrostenedione does not modulate [3H]aldosterone binding to human mononuclear leucocytes and rat renal cytosol. J Steroid Biochem Mol Biol. 1991;38:331-337.
13. Grekin RJ, Sider RS. Aldosterone receptor assay in rat kidney cytosol. J Steroid Biochem. 1980;13:835-837. (Pubitemid 11223932)
14. Kagawa CM. Blocking the renal electrolyte effects of mineralocorticoids with an orally active steroidal spirolactone. Endocrinology. 1960;67:125-132.
15. Kagawa CM, Jacobs RS Jr. Mineralocorticoid effects of 9 alpha-fluorodeoxycorticosterone in adrenalectomized rats. Proc Soc Exp Biol Med. 1960;104:60-62.
16. Sunami O, Kunimatsu T, Yamada T, Yabushita S, Sukata T, Miyata K, et al. Evaluation of a 5-day Hershberger assay using young mature male rats: methyltestosterone and p,p′-DDE, but not fenitrothion, exhibited androgenic or antiandrogenic activity in vivo. J Toxicol Sci. 2000;25:403-415. (Pubitemid 32055042)
17. Yamada T, Kunimatsu T, Sako H, Yabushita S, Sukata T, Okuno Y, et al. Comparative evaluation of a 5-day Hershberger assay utilizing mature male rats and a pubertal male assay for detection of flutamide's antiandrogenic activity. Toxicol Sci. 2000;53:289-296. (Pubitemid 30100146)
18. Zhang Z, Olland AM, Zhu Y, Cohen J, Berrodin T, Chippari S, et al. Molecular and pharmacological properties of a potent and selective novel nonsteroidal progesterone receptor agonist tanaproget. J Biol Chem. 2005;280:28468-28475. (Pubitemid 41105746)
19. Kaukonen AM, Vuorela P, Vuorela H, Mannermaa JP. High-performance liquid chromatography methods for the separation and quantitation of spironolactone and its degradation products in aqueous formulations and of its metabolites in rat serum. J Chromatogr A. 1998;797:271-281. (Pubitemid 28156970)
20. Tokumura T, Muraoka A, Masutomi T, Machida Y. Stability of spironolactone in rat plasma: strict temperature control of blood and plasma samples is required in rat pharmacokinetic studies. Biol Pharm Bull. 2005;28:1126-1128. (Pubitemid 40880332)
21. Heikinheimo O, Gordon K, Williams RF, Hodgen GD. Inhibition of ovulation by progestin analogs (agonists vs antagonists): preliminary evidence for different sites and mechanisms of actions. Contraception. 1996;53:55-64. (Pubitemid 26043594)
22. Tamura T, Yokoi R, Okuhara Y, Harada C, Terashima Y, Hayashi M, et al. Collaborative work on evaluation of ovarian toxicity. 2) Two- or four-week repeated dose studies and fertility study of mifepristone in female rats. J Toxicol Sci. 2009;34 Suppl 1:SP31-SP42.
23. Muhlemann MF, Carter GD, Cream JJ, Wise P. Oral spironolactone: an effective treatment for acne vulgaris in women. Br J Dermatol. 1986;115:227-232. (Pubitemid 16069468)
24. Moghetti P, Tosi F, Tosti A, Negri C, Misciali C, Perrone F, et al. Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. J Clin Endocrinol Metab. 2000;85:89-94. (Pubitemid 32268796)
25. Spritzer PM, Lisboa KO, Mattiello S, Lhullier F. Spironolactone as a single agent for long-term therapy of hirsute patients. Clin Endocrinol (Oxf). 2000;52:587-594. (Pubitemid 30337084)
26. Kelestimur F, Everest H, Unluhizarci K, Bayram F, Sahin Y. A comparison between spironolactone and spironolactone plus finasteride in the treatment of hirsutism. Eur J Endocrinol. 2004;150:351-354. (Pubitemid 38443786)
27. Sato A, Liu JP, Funder JW. Aldosterone rapidly represses protein kinase C activity in neonatal rat cardiomyocytes in vitro. Endocrinology. 1997;138:3410-3416. (Pubitemid 27345696)
28. Michea L, Delpiano AM, Hitschfeld C, Lobos L, Lavandero S, Marusic ET. Eplerenone blocks nongenomic effects of aldosterone on the Na+/H+ exchanger, intracellular Ca2+ levels, and vasoconstriction in mesenteric resistance vessels. Endocrinology. 2005;146:973-980. (Pubitemid 40289282)
29. Miyata Y, Muto S, Kusano E. Mechanisms for nongenomic and genomic effects of aldosterone on Na+/H+ exchange in vascular smooth muscle cells. J Hypertens. 2005;23:2237-2250. (Pubitemid 41666754)